The findings follow recent data suggesting that esophageal dysmotility may be associated with eosinophilic esophagitis (EoE), which often presents with dysphagia.
More than half of patients with eosinophilic esophagitis (EoE) present with an esophageal motility disorder, found researchers of a new analysis published in Neurogastroenterology and Motility.
Their findings follow recent data suggesting that esophageal dysmotility may be associated with EoE, which often presents with dysphagia. In the recent systematic review and meta-analysis, 53% had an abnormal motility disorder. The analysis included 400 patients spanning 14 studies using high-resolution manometry (HRM).
“Esophageal dysmotility may be due to smooth muscle dysfunction in EoE that can be induced by the interplay of eosinophils and mast cells. However, it is unclear if this acts alone as a single factor or to what extent associated inflammation, edema, or fibrosis leading to decreased compliance play a role,” explained the researchers. “The pathophysiological mechanisms that promote esophageal dysmotility in patients with EoE are not fully known, although there are several postulated theories. In some achalasia patients, degranulating eosinophils may be the mediators of destruction of myenteric plexus neurons.”
In their study, achalasia was uncommon, present in just 2% of patients. Other major motility disorders, including esophagogastric-junction outflow obstruction (10%) and hypercontractile disorder (1%), were also uncommon. Disorders of peristalsis were also less common in patients. For example, absent contractility was seen in just 5 of 345 patients in 10 studies.
Meanwhile, minor motility disorders, including ineffective esophageal motility (IEM) and fragmented peristalsis, were common in patients. The researchers noted that although IEM was prevalent among patients with EoE (18%), the proportion did not vary significantly from that of controls and patients with EOE did not have an increased risk for IEM compared with controls (odds ratio, 0.83; 95% CI, 0.30-2.27). Both IEM and fragmented peristalsis were found at a similar rate in patients with EoE and controls with gastroesophageal reflux disease.
“The etiology of these motility abnormalities is most likely multifactorial, and further studies are needed to determine the relationship between eosinophilic infiltration and abnormal esophageal motility findings,” explained the researchers. “In particular, HRM and newer techniques such as EndoFLIP should be used prospectively with Chicago 4 Classificationto provide the most up-to-date picture in a prospective fashion. From the clinical standpoint, it would be reasonable to consider esophageal manometry in EoE patients with ongoing dysphagia or chest pain symptoms that persist despite successful histologic and/or endoscopic responses to treatment.”
The researchers flagged the heterogeneity present within and between the studies included in their analysis, noting that their findings should be interpreted with caution. The group also underscored a lack of consistent endoscopic data included in some studies, leaving uncertainty of whether structural changes, such as fibrostenotic disease, was present. These structural changes, explained the researchers, may contribute to some manometric abnormalities seen in esophageal manometry.
Reference
Reddy S, Ketchem C, Dougherty M, Eluri S, Dellon E. Association between eosinophilic esophagitis and esophageal dysmotility: a systematic review and meta-analysis. Neurogastroenterol Motil. Published online September 27, 2022. doi:10.1111/nmo.14475
Rozanolixizumab Effective in Patients with MuSK MG, Analysis Shows
October 23rd 2024A new subgroup analysis of patients with muscle-specific tyrosine kinase (MuSK) autoantibody-positive (Ab+) myasthenia gravis (MG) shows rozanolixizumab (Rystiggo) contributes to meaningful symptom improvement.
Read More
Insurance Insights: Dr Jason Shafrin Estimates DMD Insurance Value
July 18th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the July 2024 issue of The American Journal of Managed Care® that estimates the insurance value of novel Duchenne muscular dystrophy (DMD) treatment.
Listen
Neoadjuvant Chemotherapy Becomes Leading Initial Treatment for Advanced Epithelial Ovarian Cancer
October 22nd 2024By 2021, neoadjuvant chemotherapy followed by interval cytoreductive surgery became the most common initial treatment for patients with advanced epithelial ovarian cancer, overtaking primary cytoreductive surgery.
Read More
From Polypharmacy to Personalized Care: Dr Nihar Desai Discusses Holistic Cardiovascular Care
May 30th 2024In this episode of Managed Care Cast, Nihar Desai, MD, MPH, cardiologist and vice chief of Cardiology at the Yale School of Medicine, discusses therapies for cardiovascular conditions as they relate to patient adherence, polypharmacy, and health access.
Listen
Delayed Diagnoses, Oxygen Therapy Use Linked to Worse Outcomes in Patients With Fibrotic ILD
October 21st 2024Posters presented at the CHEST 2024 annual meeting revealed that delays in diagnosing fibrotic interstitial lung disease (ILD) can negatively impact overall survival, while supplemental oxygen therapy may exacerbate clinical burdens through increased rates of acute exacerbations and hospitalizations.
Read More
Lower Diagnostic Error Rates Found Among Hospitalized Patients During Care Transitions
October 21st 2024Examining care transitions in hospitalized patients revealed lower diagnostic error rates compared with traditional methods, highlighting the effectiveness of this approach in identifying diagnostic challenges.
Read More